The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global RNAi Drugs Market Research Report 2024
Synopsis
It refers to the highly conservative, double stranded RNA induced, highly specific degradation of homologous mRNA in the evolutionary process
Global RNAi Drugs market is projected to reach US$ 268930 million in 2029, increasing from US$ 69200 million in 2022, with the CAGR of 21.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Drugs market research.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The RNAi Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
It refers to the highly conservative, double stranded RNA induced, highly specific degradation of homologous mRNA in the evolutionary process
Global RNAi Drugs market is projected to reach US$ 268930 million in 2029, increasing from US$ 69200 million in 2022, with the CAGR of 21.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Drugs market research.
Increasing incidence of chronic medical and genetic disorders such as cancer and cardiovascular diseases (CVDs) across the globe is one of the key factors driving the market growth. Moreover, rising geriatric population, who are more susceptible to these diseases, is also driving the growth of the market. In line with this, as the coronavirus disease (COVID-19) continues to spread globally, the demand for RNAi drug delivery technology has also increased significantly. Targeted drug delivery approaches, such as aptamer delivery systems, are gaining enormous traction for the delivery of antiviral drugs because they are induced by small interfering RNA (siRNA) and can inhibit the expression of viral antigens. Furthermore, various technological advancements such as the development of innovative synthetic delivery vehicles and biological carriers are expected to drive the market growth. Nanocarriers, including siRNA or microRNA (miRNA), are crucial for the development of personalized medicine and the identification of altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in nanotechnology and molecular diagnostics, and overall improvement in healthcare infrastructure are expected to further drive the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global RNAi Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alnylam
Novo Nordisk
Eli Lilly
Alexion
Novartis
Roche
Arrowhead Pharmaceuticals Inc.
CureVac AG
Dicerna Pharmaceuticals Inc.
Gradalis Inc.
Ionis Pharmaceuticals Inc
Merck & Co. Inc.
Moderna Inc.
SBI ALApharma
Silence Therapeutics Plc
Sirnaomics Inc.
Segment by Type
siRNA
shRNA
Other
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The RNAi Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 RNAi Drugs Market Overview
1.1 Product Overview and Scope of RNAi Drugs
1.2 RNAi Drugs Segment by Type
1.2.1 Global RNAi Drugs Market Value Comparison by Type (2023-2029)
1.2.2 siRNA
1.2.3 shRNA
1.2.4 Other
1.3 RNAi Drugs Segment by Application
1.3.1 Global RNAi Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global RNAi Drugs Market Size Estimates and Forecasts
1.4.1 Global RNAi Drugs Revenue 2018-2029
1.4.2 Global RNAi Drugs Sales 2018-2029
1.4.3 Global RNAi Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 RNAi Drugs Market Competition by Manufacturers
2.1 Global RNAi Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global RNAi Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global RNAi Drugs Average Price by Manufacturers (2018-2023)
2.4 Global RNAi Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of RNAi Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of RNAi Drugs, Product Type & Application
2.7 RNAi Drugs Market Competitive Situation and Trends
2.7.1 RNAi Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest RNAi Drugs Players Market Share by Revenue
2.7.3 Global RNAi Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 RNAi Drugs Retrospective Market Scenario by Region
3.1 Global RNAi Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global RNAi Drugs Global RNAi Drugs Sales by Region: 2018-2029
3.2.1 Global RNAi Drugs Sales by Region: 2018-2023
3.2.2 Global RNAi Drugs Sales by Region: 2024-2029
3.3 Global RNAi Drugs Global RNAi Drugs Revenue by Region: 2018-2029
3.3.1 Global RNAi Drugs Revenue by Region: 2018-2023
3.3.2 Global RNAi Drugs Revenue by Region: 2024-2029
3.4 North America RNAi Drugs Market Facts & Figures by Country
3.4.1 North America RNAi Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America RNAi Drugs Sales by Country (2018-2029)
3.4.3 North America RNAi Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe RNAi Drugs Market Facts & Figures by Country
3.5.1 Europe RNAi Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe RNAi Drugs Sales by Country (2018-2029)
3.5.3 Europe RNAi Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific RNAi Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific RNAi Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific RNAi Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific RNAi Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America RNAi Drugs Market Facts & Figures by Country
3.7.1 Latin America RNAi Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America RNAi Drugs Sales by Country (2018-2029)
3.7.3 Latin America RNAi Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa RNAi Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa RNAi Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa RNAi Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa RNAi Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global RNAi Drugs Sales by Type (2018-2029)
4.1.1 Global RNAi Drugs Sales by Type (2018-2023)
4.1.2 Global RNAi Drugs Sales by Type (2024-2029)
4.1.3 Global RNAi Drugs Sales Market Share by Type (2018-2029)
4.2 Global RNAi Drugs Revenue by Type (2018-2029)
4.2.1 Global RNAi Drugs Revenue by Type (2018-2023)
4.2.2 Global RNAi Drugs Revenue by Type (2024-2029)
4.2.3 Global RNAi Drugs Revenue Market Share by Type (2018-2029)
4.3 Global RNAi Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global RNAi Drugs Sales by Application (2018-2029)
5.1.1 Global RNAi Drugs Sales by Application (2018-2023)
5.1.2 Global RNAi Drugs Sales by Application (2024-2029)
5.1.3 Global RNAi Drugs Sales Market Share by Application (2018-2029)
5.2 Global RNAi Drugs Revenue by Application (2018-2029)
5.2.1 Global RNAi Drugs Revenue by Application (2018-2023)
5.2.2 Global RNAi Drugs Revenue by Application (2024-2029)
5.2.3 Global RNAi Drugs Revenue Market Share by Application (2018-2029)
5.3 Global RNAi Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Alnylam
6.1.1 Alnylam Corporation Information
6.1.2 Alnylam Description and Business Overview
6.1.3 Alnylam RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Alnylam RNAi Drugs Product Portfolio
6.1.5 Alnylam Recent Developments/Updates
6.2 Novo Nordisk
6.2.1 Novo Nordisk Corporation Information
6.2.2 Novo Nordisk Description and Business Overview
6.2.3 Novo Nordisk RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novo Nordisk RNAi Drugs Product Portfolio
6.2.5 Novo Nordisk Recent Developments/Updates
6.3 Eli Lilly
6.3.1 Eli Lilly Corporation Information
6.3.2 Eli Lilly Description and Business Overview
6.3.3 Eli Lilly RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly RNAi Drugs Product Portfolio
6.3.5 Eli Lilly Recent Developments/Updates
6.4 Alexion
6.4.1 Alexion Corporation Information
6.4.2 Alexion Description and Business Overview
6.4.3 Alexion RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Alexion RNAi Drugs Product Portfolio
6.4.5 Alexion Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Novartis RNAi Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Roche RNAi Drugs Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 Arrowhead Pharmaceuticals Inc.
6.6.1 Arrowhead Pharmaceuticals Inc. Corporation Information
6.6.2 Arrowhead Pharmaceuticals Inc. Description and Business Overview
6.6.3 Arrowhead Pharmaceuticals Inc. RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Arrowhead Pharmaceuticals Inc. RNAi Drugs Product Portfolio
6.7.5 Arrowhead Pharmaceuticals Inc. Recent Developments/Updates
6.8 CureVac AG
6.8.1 CureVac AG Corporation Information
6.8.2 CureVac AG Description and Business Overview
6.8.3 CureVac AG RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CureVac AG RNAi Drugs Product Portfolio
6.8.5 CureVac AG Recent Developments/Updates
6.9 Dicerna Pharmaceuticals Inc.
6.9.1 Dicerna Pharmaceuticals Inc. Corporation Information
6.9.2 Dicerna Pharmaceuticals Inc. Description and Business Overview
6.9.3 Dicerna Pharmaceuticals Inc. RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Dicerna Pharmaceuticals Inc. RNAi Drugs Product Portfolio
6.9.5 Dicerna Pharmaceuticals Inc. Recent Developments/Updates
6.10 Gradalis Inc.
6.10.1 Gradalis Inc. Corporation Information
6.10.2 Gradalis Inc. Description and Business Overview
6.10.3 Gradalis Inc. RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Gradalis Inc. RNAi Drugs Product Portfolio
6.10.5 Gradalis Inc. Recent Developments/Updates
6.11 Ionis Pharmaceuticals Inc
6.11.1 Ionis Pharmaceuticals Inc Corporation Information
6.11.2 Ionis Pharmaceuticals Inc RNAi Drugs Description and Business Overview
6.11.3 Ionis Pharmaceuticals Inc RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Ionis Pharmaceuticals Inc RNAi Drugs Product Portfolio
6.11.5 Ionis Pharmaceuticals Inc Recent Developments/Updates
6.12 Merck & Co. Inc.
6.12.1 Merck & Co. Inc. Corporation Information
6.12.2 Merck & Co. Inc. RNAi Drugs Description and Business Overview
6.12.3 Merck & Co. Inc. RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Merck & Co. Inc. RNAi Drugs Product Portfolio
6.12.5 Merck & Co. Inc. Recent Developments/Updates
6.13 Moderna Inc.
6.13.1 Moderna Inc. Corporation Information
6.13.2 Moderna Inc. RNAi Drugs Description and Business Overview
6.13.3 Moderna Inc. RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Moderna Inc. RNAi Drugs Product Portfolio
6.13.5 Moderna Inc. Recent Developments/Updates
6.14 SBI ALApharma
6.14.1 SBI ALApharma Corporation Information
6.14.2 SBI ALApharma RNAi Drugs Description and Business Overview
6.14.3 SBI ALApharma RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 SBI ALApharma RNAi Drugs Product Portfolio
6.14.5 SBI ALApharma Recent Developments/Updates
6.15 Silence Therapeutics Plc
6.15.1 Silence Therapeutics Plc Corporation Information
6.15.2 Silence Therapeutics Plc RNAi Drugs Description and Business Overview
6.15.3 Silence Therapeutics Plc RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Silence Therapeutics Plc RNAi Drugs Product Portfolio
6.15.5 Silence Therapeutics Plc Recent Developments/Updates
6.16 Sirnaomics Inc.
6.16.1 Sirnaomics Inc. Corporation Information
6.16.2 Sirnaomics Inc. RNAi Drugs Description and Business Overview
6.16.3 Sirnaomics Inc. RNAi Drugs Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Sirnaomics Inc. RNAi Drugs Product Portfolio
6.16.5 Sirnaomics Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 RNAi Drugs Industry Chain Analysis
7.2 RNAi Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 RNAi Drugs Production Mode & Process
7.4 RNAi Drugs Sales and Marketing
7.4.1 RNAi Drugs Sales Channels
7.4.2 RNAi Drugs Distributors
7.5 RNAi Drugs Customers
8 RNAi Drugs Market Dynamics
8.1 RNAi Drugs Industry Trends
8.2 RNAi Drugs Market Drivers
8.3 RNAi Drugs Market Challenges
8.4 RNAi Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
